Evidence map›Paper›PMID 36518526›Full record

ArticleNAR cancer2022

Heterogeneous nuclear ribonucleoprotein K is overexpressed in acute myeloid leukemia and causes myeloproliferation in mice via altered

Marisa J L Aitken, Prerna Malaney, Xiaorui Zhang, Shelley M Herbrich, Lauren Chan, Oscar Benitez, Ashley G Rodriguez, Huaxian Ma, Rodrigo Jacamo, Ruizhi Duan and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NAR cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Marisa J L AitkenDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Prerna MalaneyDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0002-4667-4823
Xiaorui ZhangDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shelley M HerbrichDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lauren ChanDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Oscar BenitezDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ashley G RodriguezDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Huaxian MaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rodrigo JacamoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0003-1144-3344
Ruizhi DuanSchool of Health Professions, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Todd M LinkDepartment of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Steven M KornblauDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Rashmi Kanagal-ShamannaDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Carlos E Bueso-RamosDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sean M PostDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID https://orcid.org/0000-0001-9225-200X
The University of Texas MD Anderson Cancer Center · USDartmouth College · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Personalized therapy for AML patients with a newly identified genetic alterationR01CA207204 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI POST, SEAN M · 2016 to 2020
$1.8M
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA207204
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is driven by numerous molecular events that contribute to disease progression. Herein, we identify hnRNP K overexpression as a recurrent abnormality in AML that negatively correlates with patient survival. Overexpression of hnRNP K in murine fetal liver cells results in altered self-renewal and differentiation potential. Further, murine transplantation models reveal that hnRNP K overexpression results in myeloproliferation

Identifiers

PMID36518526
PMCPMC9732523
OpenAlexW4311825271

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.